-
Get Huge: Looksmaxxing to Death Docuseries Details Tony Huge's Thailand Crimes
-
Government Overspends €607 Million on International Protection Accommodation in 2024
-
IIM Indore Announces IPMAT 2027 Exam Date for April 24
-
Palestinians Salvage Cultural Heritage from Gaza Rubble Amid Widespread Destruction
-
Quick Pressure-Cooker Beef Stew and Rice Minestrone Soup Recipes
-
Fulcrum Metals PLC Announces Publication of Updated Investor Presentation
-
Guardian Metal Resources PLC Announces Proposed Spin-Out of Non-Tungsten Projects
-
InterContinental Hotels Group PLC Announces Transaction in Own Shares - November 11
-
Fulcrum Metals PLC Announces New Critical Mineral Recoveries Expand Potential
-
6 Pieces of Furniture Worth Investing In
-
Olivier Martinez Seeks Increased Child Support from Halle Berry Following Custody Change
-
Police Investigate Bedford Parent for Hallway Incident After Playoff Loss
-
Joe Biden Makes Surprise Appearance at Trinity College Dublin for Hunter's Medal
-
Regal Cinemas Launches 4DX Screenings for 'Heated Rivalry' Amid Immersive Theater Trend
-
Bank of Korea Governor Shin Hyun-song Appointed First Asian Chair of BIS Payment Committee
Moderna to Present at Upcoming Conferences in December 2024
Moderna, Inc. (Nasdaq:MRNA), today announced its participation in the following upcoming investor conferences:
7th Annual Evercore ISI HealthCONx Conference, on Wednesday, December 4th at 1:20pm ET
Piper Sandler 36th Annual Healthcare Conference, on Thursday, December 5th at 10:30am ET
A live webcast of each of these presentations will be available under "Events and Presentations" in the Investors section of the Moderna website at investors.modernatx.com. A replay of each webcast will be archived on Moderna's website for at least 30 days following the presentation.
About Moderna
Moderna is a leader in the creation of the field of mRNA medicine. Through the advancement of mRNA technology, Moderna is reimagining how medicines are made and transforming how we treat and prevent disease for everyone. By working at the intersection of science, technology and health for more than a decade, the company has developed medicines at unprecedented speed and efficiency, including one of the earliest and most effective COVID-19 vaccines.
Moderna's mRNA platform has enabled the development of therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases and autoimmune diseases. With a unique culture and a global team driven by the Moderna values and mindsets to responsibly change the future of human health, Moderna strives to deliver the greatest possible impact to people through mRNA medicines. For more information about Moderna, please visit modernatx.com and connect with us on X (formerly Twitter), Facebook, Instagram, YouTube and LinkedIn.
Investors:
Lavina Talukdar
Senior Vice President & Head of Investor Relations
617-209-5834
[email protected]
SOURCE: Moderna, Inc.
E.Flores--AT